First National Bank of Omaha decreased its stake in shares of Allergan plc (NYSE:AGN) by 29.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,270 shares of the company’s stock after selling 11,420 shares during the period. First National Bank of Omaha’s holdings in Allergan were worth $5,195,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Gradient Investments LLC grew its stake in Allergan by 747.5% during the third quarter. Gradient Investments LLC now owns 678 shares of the company’s stock worth $129,000 after buying an additional 598 shares during the period. Flagship Harbor Advisors LLC purchased a new stake in Allergan during the second quarter worth approximately $129,000. Kaizen Advisory LLC grew its stake in Allergan by 156.2% during the second quarter. Kaizen Advisory LLC now owns 830 shares of the company’s stock worth $138,000 after buying an additional 506 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its stake in Allergan by 3,193.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock worth $165,000 after buying an additional 958 shares during the period. Finally, BLB&B Advisors LLC purchased a new stake in Allergan during the third quarter worth approximately $206,000. 77.55% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Joseph H. Boccuzi acquired 900 shares of Allergan stock in a transaction on Thursday, August 30th. The shares were purchased at an average cost of $190.59 per share, for a total transaction of $171,531.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Christopher J. Coughlin acquired 10,000 shares of Allergan stock in a transaction on Thursday, September 6th. The shares were bought at an average price of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.37% of the stock is currently owned by corporate insiders.
Shares of AGN stock opened at $165.21 on Wednesday. The firm has a market capitalization of $54.99 billion, a PE ratio of 10.10, a PEG ratio of 1.29 and a beta of 1.31. The company has a quick ratio of 0.78, a current ratio of 0.92 and a debt-to-equity ratio of 0.32. Allergan plc has a twelve month low of $142.81 and a twelve month high of $197.00.
Allergan (NYSE:AGN) last announced its earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.21. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.89 billion. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.15 earnings per share. On average, research analysts predict that Allergan plc will post 16.42 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 14th. Stockholders of record on Tuesday, November 13th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, November 9th. This represents a $2.88 annualized dividend and a dividend yield of 1.74%. Allergan’s dividend payout ratio (DPR) is presently 17.61%.
AGN has been the subject of several research reports. Zacks Investment Research downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Credit Suisse Group set a $213.00 price objective on shares of Allergan and gave the stock a “buy” rating in a research note on Friday, July 13th. Wells Fargo & Co set a $240.00 price objective on shares of Allergan and gave the stock a “buy” rating in a research note on Thursday, July 19th. Cantor Fitzgerald set a $180.00 price objective on shares of Allergan and gave the stock a “hold” rating in a research note on Thursday, July 19th. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $164.00 price objective on shares of Allergan in a research note on Thursday, July 26th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $210.18.
TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/07/allergan-plc-agn-shares-sold-by-first-national-bank-of-omaha.html.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
See Also: Cash Flow
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.